Cargando…
Safety of an immunomodulator Mycobacterium w in COVID-19
Autores principales: | Sehgal, Inderpaul Singh, Bhalla, Ashish, Puri, Goverdhan Dutt, Yaddanapudi, Laxmi Narayana, Singh, Mini, Malhotra, Pankaj, Dhooria, Sahajal, Suri, Vikas, Agarwal, Ritesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353938/ https://www.ncbi.nlm.nih.gov/pubmed/32367857 http://dx.doi.org/10.4103/lungindia.lungindia_242_20 |
Ejemplares similares
-
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
por: Dhooria, Sahajal, et al.
Publicado: (2022) -
The Conundrum of ‘Long-COVID-19ʹ: A Narrative Review
por: Garg, Mandeep, et al.
Publicado: (2021) -
Computed tomography chest in COVID-19: When & why?
por: Garg, Mandeep, et al.
Publicado: (2021) -
Transforming a General Hospital to an Infectious Disease Hospital for COVID-19 Over 2 Weeks
por: Pandey, Navin, et al.
Publicado: (2020) -
Bacterial coinfections and secondary infections in COVID-19 patients from a tertiary care hospital of northern India: Time to adhere to culture-based practices
por: Sharma, Bhawna, et al.
Publicado: (2021)